JNJ : Analysis & Opinions

  • Showing 1-100 of 247 items
  • 1
  • 2
  • 3
  • >>
  1. CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst ...

    January 26, 2015
    CytRx Corporation (CYTR) announced encouraging data on its oncology candidate, aldoxorubicin.
  2. AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst ...

    January 26, 2015
    AstraZeneca (AZN) announced that its Marketing Authorisation Application for the approval of lesinurad was accepted by the ...
  3. Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst ...

    January 23, 2015
    Minerva Neurosciences, Inc. announced encouraging preliminary results from a phase I study on its sleep disorder candidate, ...
  4. Dow 30 Stock Roundup: AmEx, UnitedHealth Beat, IBM Earnings Fall ...

    January 23, 2015
    The Dow experienced a holiday shortened but successful week, boosted by monetary stimulus from the European Central Bank. ...
  5. Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst ...

    January 22, 2015
    Novartis (NVS) announced that the FDA has approved Cosentyx for the treatment of moderate-to-severe plaque psoriasis in adult ...
  6. How the S&P 500 and Russell 2000 Indexes Differ

    January 22, 2015
    The S&P 500 and Russell 2000 are used as benchmarks for broader segments of the U.S. stock market. Each index has its own ...
  7. Natus Medical's a Strong Buy on Expanding Product Portfolio - ...

    January 22, 2015
    On Jan 22, 2015, Zacks Investment Research raised Natus Medical Inc. (BABY) to a Zacks Rank #1 (Strong Buy).
  8. Bayer Announces Updates to European Label of Xarelto - Analyst ...

    January 21, 2015
    Bayer (BAYRY) announced that the label for its anticoagulant drug Xarelto will now include specific guidance for doctors ...
  9. Healthcare ETFs in Focus on Mixed JNJ Results - ETF News And ...

    January 21, 2015
    Healthcare ETFs are worth look following Johnson & Johnson mixed fourth quarter results.
  10. Stock Market News for January 21, 2015 - Market News

    January 21, 2015
    Benchmarks ended Tuesday’s choppy trading session in the green led by gains from technology shares
  11. Evotec Signs New Deal for Addictive Disorder Therapies - Analyst ...

    January 20, 2015
    Evotec AG (EVTCY) entered into a research collaboration agreement with C4X Discovery Holdings plc for the development of ...
  12. Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - ...

    January 20, 2015
    Positive news flowed in for Novartis AG (NVS) when the European Commission approved its biologic Cosentyx (secukinumab) for ...
  13. J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst ...

    January 20, 2015
    J&J's fourth quarter results were mixed with the company beating on earnings and missing on revenues.
  14. Stock Market News for January 20, 2015 - Market News

    January 20, 2015
    Markets were closed on Monday due to the Martin Luther King Jr. Day holiday
  15. IMF Cuts, Q4 Earnings Mixed - Ahead of Wall Street

    January 20, 2015
    This morning, the International Monetary Fund (IMF) lowered its global growth forecast by 30 basis points, while big players ...
  16. Will Pharmaceutical Segment Drive J&J Q4 Earnings Again? - Analyst ...

    January 19, 2015
    Will pharma product sales and newly launched products continue to be the driving force in the fourth quarter?
  17. Q4 Earnings Take a Breather for MLK Day - Ahead of Wall Street

    January 19, 2015
    Aside from a typically favorable earnings report out of Intel last week, most numbers from the big names reporting thus far ...
  18. Hospira Submits Retacrit Regulatory Application to the FDA - ...

    January 16, 2015
    Hospira, Inc. (HSP) announced that it has submitted a Biologics License Application looking to get Retacrit approved in the ...
  19. Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst ...

    January 15, 2015
    Isis Pharmaceuticals (ISIS) earned a milestone payment of $7 million from partner Biogen for the advancement of the ongoing ...
  20. CONMED Announces Preliminary FY14 Results, Guides FY15 - Analyst ...

    January 15, 2015
    CONMED Corporation (CNMD) estimates full-year 2014 revenues in the range of $739-$741 million while adjusted earnings are ...
  21. Roche to Acquire Up to 56% Interest in Foundation Medicine - ...

    January 14, 2015
    Oncology major, Roche (RHHBY) recently announced that it has entered into a strategic collaboration agreement to acquire ...
  22. DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst ...

    January 14, 2015
    Developer of continuous glucose monitoring systems, DexCom Inc. (DXCM), recently announced preliminary product revenues for ...
  23. Stryker's (SYK) Preliminary Earnings Results Raise Concern - ...

    January 14, 2015
    Stryker Corporation's (SYK) fourth-quarter and full-year projections compare unfavorably with their corresponding Zacks Consensus ...
  24. Pharmacyclics Reports Preliminary Results and 2015 Outlook - ...

    January 13, 2015
    Pharmacyclics, Inc. (PCYC) provided preliminary 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook ...
  25. Dow 30 Stock Roundup: Pfizer Acquires Redvax, Microsoft Launches ...

    January 9, 2015
    The Dow started the week on a poor note before recovering considerably.
  26. Isis Pharmaceuticals Improves 2014 Outlook, Shares Up - Analyst ...

    January 9, 2015
    Isis Pharmaceuticals (ISIS) gained around 4.9% after the company updates its 2014 outlook.
  27. Natus Medical Advances Newborn Care with Nicview Buyout - Analyst ...

    January 8, 2015
    Natus Medical Inc (BABY) is presently focusing on enhancing its offerings for the newborn care market
  28. J&J Starts Ebola Vaccine Study, Updates Production Goal - Analyst ...

    January 7, 2015
    Johnson & Johnson (JNJ) commenced a phase I study on a preventive Ebola vaccine to evaluate the safety and tolerability ...
  29. Alere's (ALR) Influenza Test Gets CLIA Waiver from the FDA - ...

    January 7, 2015
    With the CLIA waiver from the FDA, Alere Inc.'s (ALR) i Influenza A & B test can now be used across a wide variety of ...
  30. 2 Pharmaceutical Stocks Ready to Beat Earnings This Quarter - ...

    January 6, 2015
    These two pharma stocks could be great picks this earnings season.
  31. Pharmacyclics Reports Encouraging Data on Cancer Drug - Analyst ...

    January 6, 2015
    Pharmacyclics, Inc. (PCYC) announced encouraging data on its oncology drug, Imbruvica.
  32. Isis Pharmaceuticals Up on Collaboration with J&J - Analyst ...

    January 6, 2015
    Isis Pharmaceuticals (ISIS) inked a global collaboration with Johnson & Johnson's (JNJ) Janssen Biotech, Inc for the ...
  33. Cooper Companies Makes MyDay Available in Hong Kong - Analyst ...

    January 5, 2015
    The Cooper Companies Inc. (COO), a medical device company known for its wide range of contact lenses, recently made its MyDay ...
  34. Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst ...

    December 31, 2014
    Idera Pharmaceuticals (IDRA) announced that the FDA has granted orphan drug designation to IMO-8400.
  35. Gilead/J&J Expand TAF-based HIV Drugs Related Agreement - Analyst ...

    December 30, 2014
    Gilead Sciences, Inc. announced that it has expanded its agreement with Janssen R&D Ireland, a subsidiary of Johnson ...
  36. 3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog

    December 30, 2014
    Gilead (GILD) has been under pressure due to the pricing of its hepatitis C virus (HCV) treatments.
  37. Tetraphase Hits 52-Week High on Positive Antibiotic Data - Analyst ...

    December 29, 2014
    Shares of Tetraphase Pharmaceuticals, Inc. have been riding high after the company announced positive top-line data from ...
  38. After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst ...

    December 26, 2014
    Gilead Sciences Inc. has plunged approximately 15.8% after pharmacy benefit manager Express Scripts entered into an agreement ...
  39. 4 Biotech Stocks that Doubled in 2014 - Analyst Blog

    December 26, 2014
    Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech ...
  40. Integra LifeSciences Hits 52-Week High on Portfolio Strength ...

    December 24, 2014
    Over the last few months, Integra LifeSciences Holdings Corporation (IART) has launched back-to-back products which we believe ...
  41. Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst ...

    December 23, 2014
    Pharmacyclics, Inc. (PCYC) announced that the FDA is expected to render a final opinion on the supplemental New Drug Application ...
  42. Achillion Gains on Positive Results from its HCV Candidates - ...

    December 23, 2014
    Achillion Pharmaceuticals (ACHN) gained more than 9% after announcing encouraging results from its HCV candidates.
  43. Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst ...

    December 23, 2014
    Pharmacy benefit manager Express Scripts (ESRX) announced an update to its National Preferred Formulary, which will now include ...
  44. MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst ...

    December 23, 2014
    MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development ...
  45. AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst ...

    December 22, 2014
    AbbVie's (ABBV) Viekira Pak will be entering the HCV market which is currently dominated by Gilead.
  46. Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst ...

    December 22, 2014
    Celgene Corporation announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered ...
  47. Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst ...

    December 19, 2014
    Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the ...
  48. Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst ...

    December 18, 2014
    Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson ...
  49. CR Bard Strong on Acquisitions, FDA Nod for Lutonix DCB - Analyst ...

    December 17, 2014
    CR Bard's initiative to introduce its products in the emerging markets is delivering accretive returns, as the company continues ...
  50. 3 U.S. Medical Devices Stocks That Surged in 2014 - Analyst Blog

    December 17, 2014
    The prospects of the medical devices industry have improved following a Republican victory in the midterm elections.
  51. Most Powerful And Influential Public Companies In 3 Metrics

    December 9, 2014
    There are many ways to rank the word's most powerful companies. Looking at market value, brand value or sales revenue are ...
  52. Will MedTech Gain from Republican Promises? - Industry Outlook

    December 4, 2014
    Will MedTech Gain from Republican Promises? - Industry Outlook
  53. This ETF Offers Easy Access To Big Pharma

    November 21, 2014
    Pharma investing isn't for everyone, but sector-specific ETFs, such as the iShares Dow Jones U.S. Pharmaceuticals ETF, have ...
  54. 3 Healthcare Stocks To Hedge Against Rising Medical Costs

    October 29, 2014
  55. 3 Healthcare Stocks To Profit From An Aging America

    October 29, 2014
  56. How do you compare the Dow Jones Industrial Average (DJIA) and ...

    October 2, 2014
    See how the Dow Jones Industrial Average and TSX Composite move according to factors in their respective countries and from ...
  57. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  58. Shocking Prediction #9: 'Nightmare Pandemics' Could Make These ...

    August 27, 2014
    Let me start off today's issue with a warning... We're not trying to sound alarmist. It does absolutely zero good ...
  59. MedTech Defies Sequestration, M&As Steal the Show - Industry ...

    August 26, 2014
    MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
  60. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  61. A Good Start to Q2 Earnings Season - Earnings Trends

    July 16, 2014
    A Good Start to Q2 Earnings Season - Earnings Trends
  62. More Good News to Backstop Market - Ahead of Wall Street

    July 15, 2014
    Stocks today will likely maintain the positive momentum of the last few sessions, and Janet Yellen's Senate testimony comes ...
  63. Is Now The Time For Momentum Stocks?

    July 11, 2014
    In active trading, strong trends can last longer than traders expect. This has led to a surge of purpose-built exchange traded ...
  64. Interested In Healthcare Stocks? Look At This ETF

    July 3, 2014
    Healthcare companies seem to be poised to make a move higher over the months ahead. Here's an ETF that should be helpful ...
  65. This Company Is No Mickey Mouse Operation

    June 4, 2014
    With its famous history that's become part of popular culture, and the instantly recognizable silhouette in its logo, The ...
  66. MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook

    May 1, 2014
    MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
  67. How Johnson & Johnson Became A Household Name

    April 21, 2014
    New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household ...
  68. How Some Brands Come Back from Near Death

    April 17, 2014
    Some company brands manage to revive themselves, while others die and go to brand heaven.
  69. Earnings Outlook is the Key Factor - Ahead of Wall Street

    April 15, 2014
    My sense is that it will be very hard for the stock market to get its mojo back unless the earnings outlook improves.
  70. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  71. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  72. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  73. How To Smooth-Out Your Ride In The Stock Market

    March 3, 2014
    Volatility is back. For investors, this nasty problem of gyrating markets can be a real hindrance to your portfolio’s total ...
  74. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  75. Bull of the Day: Valeant Pharma (VRX) - Bull of the Day

    October 13, 2013
    Bull of the Day: Valeant Pharma (VRX) - Bull of the Day
  76. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  77. 14 Companies That Have Raised Their Dividends For 50 Years Or ...

    September 10, 2013
    Imagine if you had bought these stocks 20 years ago.If you had, then right now you'd be earning dividend yields of... ...
  78. MedTech Industry Stock Update - Sept 2013 - Industry Outlook

    September 10, 2013
    MedTech Industry Stock Update - Sept 2013 - Industry Outlook
  79. Akorn Scores A Rare Win-Win Acquisition

    August 27, 2013
    Akorn builds value by buying Hi-Tech
  80. Medtronic Marking Time

    August 20, 2013
    Medtronic looks stuck in low-growth mode for now, but the shares look undervalued.
  81. Danaher Could Be Loading Up For A Bigger 2014

    August 14, 2013
    Danaher has the resources to make some major purchases, but prices and expectations may be a little high.
  82. The Street Has Caught Covidien

    August 1, 2013
    Covidien's quality isn't the issue, but Wall Street's love for it may be.
  83. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  84. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  85. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  86. Stryker Seems Back On Track

    July 19, 2013
    Stryker's revenue growth looks fine, but there are still pressures in the end markets.
  87. Where Do The Bears Go Next With St. Jude Medical?

    July 18, 2013
    St. Jude continues to defy bearish expectations of major share loss, but the shares aren't exactly cheap today.
  88. Abbott Labs Making Progress On Margins, Now It Needs More Growth

    July 17, 2013
    Abbott's results were just so-so, as both margins and growth need more momentum.
  89. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  90. Prestige Brands Gets Upgraded: Should You Be Buying?

    July 11, 2013
    At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian ...
  91. Intuitive Surgical's Miss Looks Systemic And Company-Specific

    July 9, 2013
    A surprising drop in U.S. system placements is going to put Intuitive Surgical in the penalty box.
  92. Profiting With Straddles This Earnings Season - Know Your Options

    July 2, 2013
    Profiting With Straddles This Earnings Season - Know Your Options
  93. CHMP Positive on Dendreon's Provenge - Analyst Blog

    July 1, 2013
    The CHMP provided a positive opinion on Dendreon's marketing application for Provenge.
  94. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  95. Data from Bayer/JNJ's Xarelto Study - Analyst Blog

    June 25, 2013
    Bayer's announced that it will present data from a Xarelto clinical program.
  96. Rising 10-Year Yields Could Crush Popular Dividend ETFs

    June 21, 2013
    Seduced by backward-looking dividend increase streaks, investors have fallen in love with dividend ETFs such as the Vanguard ...
  97. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  98. Little Left To Dendreon But The Hope Trade

    May 10, 2013
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  99. Recent Financials May Not Be Entirely Fair To Hologic

    May 8, 2013
    Macro pressures are outweighing solid internal progress at Hologic.
  100. In A Growth-Starved Sector, Becton Dickinson Rules

    May 3, 2013
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth. ...
  • Showing 1-100 of 247 items
  • 1
  • 2
  • 3
  • >>
Trading Center